sacituzumab
gilead sciences
['biomarker', 't-dxd', 'sacituzumab', 'sacitu, govi', 'tropics-02', 'marker ']
tropics-02: presents a statistically significant mos benefit of 3 months.
i guess we need a biomarker to identify patients benefiting the most from sacituzumab govitecan in a setting for which treatment options are increasing (eg. t-dxd). #esmo22 
MD (Oncology registrar) & Researcher @Hopitaux_unige (Geneva,CH) •PhD (@Cambridge_Uni) •MPH @LSHTM